JAK1

Across TCGA pan-cancer cohorts, JAK1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JAK1 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher JAK1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JAK1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where JAK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	1.000	0.346	.004	14	view →
LSCC	DFS	Median	II,III,IV	0.546	0.848	.009	10	view →
HNSC	DFS	Median	II,III,IV	0.888	0.993	.002	10	view →
UCEC	DFS	Median	II,III,IV	0.826	1.000	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JAK1–PDAC (DFS)

Open the PDAC breakdown →